文献速递认知障碍与痴呆

Semorinemab在阿尔茨海默病前驱期至轻度阶段患者中的安全性和有效性:一项随机临床试验

Safety and Efficacy of Semorinemab in Individuals With Prodromal to Mild Alzheimer Disease: A Randomized Clinical Trial.
PubMed 文献 · JAMA Neurol · 2022-01-01

这项2期随机双盲安慰剂对照平行组试验在北美、欧洲和澳大利亚97个中心纳入前驱期至轻度阿尔茨海默病患者,比较semorinemab三个剂量与安慰剂的疗效和安全性。73周内各组临床痴呆评定量表-总和评分类似升高,semorinemab未减缓临床进展,但安全性可接受且耐受良好。

要点

  • semorinemab三个剂量组与安慰剂组在73周时临床痴呆评定量表-总和评分升高程度相似,未减缓临床进展。
  • semorinemab安全性可接受且耐受良好,不良事件比例与安慰剂组相似。
  • 作者认为可能需要进一步研究抗tau抗体以确定该治疗方法的临床效用。

核心结论

  • 在前驱期至轻度阿尔茨海默病患者中,semorinemab在73周研究期间未减缓临床进展,但安全性可接受且耐受良好。
  • 作者认为可能需要进一步研究抗tau抗体以确定该治疗方法的临床效用。

研究设计与样本

  • 这是一项2期随机、双盲、安慰剂对照、平行组临床试验,于2017年10月18日至2020年7月16日在北美、欧洲和澳大利亚97个中心开展。
  • 纳入年龄50至80岁(含)、简易精神状态检查评分20至30分(含)、经正电子发射断层扫描或脑脊液确认β-淀粉样蛋白病理的前驱期至轻度阿尔茨海默病患者。
  • 在73周盲法研究期间,参与者接受静脉输注安慰剂或semorinemab(1500 mg、4500 mg或8100 mg),前3次每2周一次,此后每4周一次。
  • 改良意向治疗队列共422例(平均[标准差]年龄69.6[7.0]岁;女性235例[55.7%]),安全性可评估队列共441例。

主要发现

  • 改良意向治疗队列中,临床痴呆评定量表-总和评分从基线至第73周的变化:安慰剂组(n=126)Δ=2.19(95%CI 1.74-2.63);semorinemab 1500 mg组(n=86)Δ=2.36(95%CI 1.83-2.89);4500 mg组(n=126)Δ=2.36(95%CI 1.92-2.79);8100 mg组(n=84)Δ=2.41(95%CI 1.88-2.94),各组升高程度相似。
  • 安全性可评估队列中,发生不良事件的比例:安慰剂组130例(93.1%);semorinemab 1500 mg组89例(88.8%);4500 mg组132例(94.7%);8100 mg组90例(92.2%),各组比例相似。

关键数值与推荐

  • 主要结局为临床痴呆评定量表-总和评分从基线至第73周的变化,以及semorinemab与安慰剂相比的安全性和耐受性评估。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 作者在结论中提出,可能需要进一步研究抗tau抗体以确定该治疗方法的临床效用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Neurofibrillary tangles composed of aggregated tau protein are one of the neuropathological hallmarks of Alzheimer disease (AD) and correlate with clinical disease severity. Monoclonal antibodies targeting tau may have the potential to ameliorate AD progression by slowing or stopping the spread and/or accumulation of pathological tau. OBJECTIVE: To evaluate the safety and efficacy of the monoclonal anti-tau antibody semorinemab in prodromal to mild AD. DESIGN, SETTING, AND PARTICIPANTS: This phase 2 randomized, double-blind, placebo-controlled, parallel-group clinical trial was conducted between October 18, 2017, and July 16, 2020, at 97 sites in North America, Europe, and Australia. Individuals aged 50 to 80 years (inclusive) with prodromal to mild AD, Mini-Mental State Examination scores between 20 and 30 (inclusive), and confirmed β-amyloid pathology (by positron emission tomography or cerebrospinal fluid) were included. INTERVENTIONS: During the 73-week blinded study period, participants received intravenous infusions of placebo or semorinemab (1500 mg, 4500 mg, or 8100 mg) every 2 weeks for the first 3 infusions and every 4 weeks thereafter. MAIN OUTCOMES AND MEASURES: The primary outcomes were change from baseline on the Clinical Dementia Rating-Sum of Boxes score from baseline to week 73 and assessments of the safety and tolerability for semorinemab compared with placebo. RESULTS: In the modified intent-to-treat cohort (n = 422; mean [SD] age, 69.6 [7.0] years; 235 women [55.7%]), similar increases were seen on the Clinical Dementia Rating-Sum of Boxes score in the placebo (n = 126; Δ = 2.19 [95% CI, 1.74-2.63]) and semorinemab (1500 mg: n = 86; Δ = 2.36 [95% CI, 1.83-2.89]; 4500 mg: n = 126; Δ = 2.36 [95% CI, 1.92-2.79]; 8100 mg: n = 84; Δ = 2.41 [95% CI, 1.88-2.94]) arms. In the safety-evaluable cohort (n = 441), similar proportions of participants experienced adverse events in the placebo (130 [93.1%]) and semorinemab (1500 mg: 89 [88.8%]; 4500 mg: 132 [94.7%]; 8100 mg: 90 [92.2%]) arms. CONCLUSIONS AND RELEVANCE: In participants with prodromal to mild AD in this randomized clinical trial, semorinemab did not slow clinical AD progression compared with placebo throughout the 73-week study period but did demonstrate an acceptable and well-tolerated safety profile. Additional studies of anti-tau antibodies may be needed to determine the clinical utility of this therapeutic approach. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03289143.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. Teng E, Manser PT, Pickthorn K, et al. Safety and Efficacy of Semorinemab in Individuals With Prodromal to Mild Alzheimer Disease: A Randomized Clinical Trial. JAMA Neurol. 2022. PMID: 35696185. doi:10.1001/jamaneurol.2022.1375

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。